2020
Circulating markers of angiogenesis and endotheliopathy in COVID‐19
Pine AB, Meizlish ML, Goshua G, Chang C, Zhang H, Bishai J, Bahel P, Patel A, Gbyli R, Kwan JM, Won CH, Price C, Dela Cruz CS, Halene S, van Dijk D, Hwa J, Lee AI, Chun HJ. Circulating markers of angiogenesis and endotheliopathy in COVID‐19. Pulmonary Circulation 2020, 10: 1-4. PMID: 33282193, PMCID: PMC7691906, DOI: 10.1177/2045894020966547.Peer-Reviewed Original ResearchCOVID-19 infectionMarkers of angiogenesisEndothelial injuryDisease severityCOVID-19-associated coagulopathyCritical COVID-19 infectionCOVID-19 pathogenesisCOVID-19COVID-19 diseaseEndothelial cell functionHospital mortalityMicrovascular complicationsCritical illnessElevated markersHospitalized patientsPatient populationFuture therapiesPlasma profilingSurvival analysisPatientsInfectionCell functionPotential targetInjuryMarkers
2009
Regional hypoxia correlates with the uptake of a radiolabeled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury.
Dobrucki LW, Meoli DF, Hu J, Sadeghi MM, Sinusas AJ. Regional hypoxia correlates with the uptake of a radiolabeled targeted marker of angiogenesis in rat model of myocardial hypertrophy and ischemic injury. Journal Of Physiology And Pharmacology 2009, 60 Suppl 4: 117-23. PMID: 20083860.Peer-Reviewed Original ResearchConceptsMyocardial hypertrophyHypoxic myocardiumMyocardial infarctionRat modelPressure overload-induced myocardial hypertrophyNon-invasive imaging strategyDeficient blood flowDegree of hypoperfusionAbdominal aortic bandingAnterior lateral wallLeft ventricular remodelingIschemic rat modelMarkers of angiogenesisHypoxia-induced angiogenesisPotential clinical useIschemic injuryAortic bandingVentricular remodelingAlphavbeta3 integrin receptorMyocardial hypoxiaImmunohistochemical stainingMyocardial uptakeRodent modelsBlood flowMyocardial segmentsPhase II study of sunitinib in men with advanced prostate cancer
Michaelson M, Regan M, Oh W, Kaufman D, Olivier K, Michaelson S, Spicer B, Gurski C, Kantoff P, Smith M. Phase II study of sunitinib in men with advanced prostate cancer. Annals Of Oncology 2009, 20: 913-920. PMID: 19403935, PMCID: PMC2674960, DOI: 10.1093/annonc/mdp111.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAngiogenesis InhibitorsAngiogenic ProteinsAntineoplastic Agents, PhytogenicDocetaxelDrug Resistance, NeoplasmHumansIndolesMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsProtein Kinase InhibitorsPyrrolesRadiographySunitinibTaxoidsTime FactorsTreatment OutcomeConceptsCastration-resistant prostate cancerProstate cancerPhase II study of sunitinibSoluble vascular endothelial growth factor receptor-2Group AInhibitors of tyrosine kinase receptorsSerum markers of angiogenesisTolerability of sunitinibTreated with sunitinibAdvanced prostate cancerPhase II studyStudy of sunitinibEffects of sunitinibSecondary end pointsVascular endothelial growth factor receptor 2Placental growth factorCommon adverse effectsEndothelial growth factor receptor 2Platelet-derived growth factor-AAMarkers of angiogenesisPost-treatment declinesTyrosine kinase receptorsOn-target effectsPSA declineStable PSA
2008
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. British Journal Of Cancer 2008, 99: 68-71. PMID: 18560403, PMCID: PMC2453019, DOI: 10.1038/sj.bjc.6604443.Peer-Reviewed Original ResearchConceptsCollagen IV levelsHealthy womenCancer patientsBreast cancerPreoperative chemotherapySerum levelsCollagen IVBaseline serum levelsSerum collagen IVPrimary breast cancerBreast cancer patientsSera of patientsMarkers of angiogenesisSandwich enzyme-linked immunoassayEnzyme-linked immunoassayCollagen IV concentrationVascular basement membraneClinical stageHER2 statusHealthy controlsSignificant further increaseHealthy volunteersPatientsChemotherapyStage IITargeted imaging of hypoxia-induced integrin activation in myocardium early after infarction
Kalinowski L, Dobrucki LW, Meoli DF, Dione DP, Sadeghi MM, Madri JA, Sinusas AJ. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. Journal Of Applied Physiology 2008, 104: 1504-1512. PMID: 18356482, DOI: 10.1152/japplphysiol.00861.2007.Peer-Reviewed Original ResearchMeSH KeywordsActinsAnimalsBiomarkersBiotransformationDogsHeterocyclic Compounds, 1-RingHypoxiaImidazolesImmunohistochemistryIntegrin alphaVbeta3IntegrinsMaleMyocardial InfarctionMyocardial IschemiaMyocardiumNeovascularization, PhysiologicOrganometallic CompoundsOrganotechnetium CompoundsRadiopharmaceuticalsRatsRats, Sprague-DawleyTechnetium Tc 99m SestamibiTomography, Emission-Computed, Single-PhotonConceptsMyocardial infarctionInfarct regionCanine studyIschemic heart diseaseCoronary artery occlusionAcute myocardial infarctionMarkers of angiogenesisEx vivo analysisExpression/activationPotential novel targetHypoxia-induced angiogenesisVivo SPECT imagingAlphavbeta3 integrinBRU59-21Artery occlusionNovel noninvasive approachHeart diseaseHistological evidenceMyocardial hypoxiaMyocardial uptakeRP748Rodent studiesAngiogenic therapyInfarctionMyocardial angiogenesis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply